Neuromuscular blockades are also called muscle relaxants. They minimize seizures and decrease the risk of injury during the procedure. They are given to prevent musculoskeletal complications such as myalgia, bone fractures, and dislocations and are given to patients with hypercalcemia, osteoporosis, malignant hyperthermia, or pseudocholinesterase deficiency. The patient requires physical restraint if neuromuscular blockades are not administered. Following muscle relaxants are used: • Succinylcholine • Mivacurium • Atracurium • Vecuronium • Rapacurinium Succinylcholine is the commonest neuromuscular blocker with a short duration of action. Patients with a history of bradyarrhythmias should avoid large doses of succinylcholine while small doses of this muscle relaxants can produce side effects like myalgia, hyperthermia, and hyperkalemia in patients with a risk of malignant hyperthermia, neuroleptic malignant syndrome, and catatonic schizophrenia. Mivacurium is a short-acting relaxant and is administered alternative to succinylcholine. Histamine release and hypotension can be induced due to a full dose of mivacurium and will require anticholinesterase drugs to reverse residual paralysis. Vecuronium is used in patients with severe succinylcholine induced myalgias. Rapacuronium has a rapid onset and short duration of action. It is used in patients with a family history of malignant hyperthermia. Before the procedure begins, muscle relaxation is confirmed by checking for loss of deep tendon reflexes.